Xencor Inc (XNCR) Expected to Post Quarterly Sales of $60.05 Million

Share on StockTwits

Wall Street analysts predict that Xencor Inc (NASDAQ:XNCR) will announce $60.05 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Xencor’s earnings, with the lowest sales estimate coming in at $13.90 million and the highest estimate coming in at $126.25 million. The company is expected to issue its next quarterly earnings results on Monday, May 6th.

According to Zacks, analysts expect that Xencor will report full-year sales of $102.90 million for the current financial year, with estimates ranging from $59.10 million to $147.50 million. For the next financial year, analysts forecast that the company will post sales of $82.02 million, with estimates ranging from $8.00 million to $124.50 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover Xencor.

Xencor (NASDAQ:XNCR) last released its earnings results on Monday, February 25th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.21. The company had revenue of $11.56 million for the quarter.

XNCR has been the topic of several research analyst reports. Guggenheim initiated coverage on shares of Xencor in a research report on Friday, April 12th. They set a “buy” rating and a $42.00 target price on the stock. Cantor Fitzgerald reiterated a “buy” rating and issued a $40.00 target price on shares of Xencor in a research note on Tuesday, April 2nd. Berenberg Bank began coverage on shares of Xencor in a research note on Wednesday, March 27th. They issued a “buy” rating and a $45.00 target price for the company. ValuEngine cut shares of Xencor from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 28th. Finally, BidaskClub cut shares of Xencor from a “buy” rating to a “hold” rating in a research note on Wednesday, January 16th. Two analysts have rated the stock with a sell rating and ten have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $41.49.

NASDAQ:XNCR traded up $1.18 during trading hours on Friday, hitting $32.13. 959 shares of the company were exchanged, compared to its average volume of 216,566. The company has a market cap of $1.79 billion, a PE ratio of -24.40 and a beta of 1.35. Xencor has a 52-week low of $27.75 and a 52-week high of $48.38.

In other Xencor news, major shareholder John S. Stafford III bought 5,500 shares of the company’s stock in a transaction dated Monday, March 25th. The stock was acquired at an average price of $29.84 per share, with a total value of $164,120.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder John S. Stafford III bought 1,100 shares of the company’s stock in a transaction dated Monday, March 18th. The shares were acquired at an average cost of $29.90 per share, with a total value of $32,890.00. The disclosure for this purchase can be found here. Insiders have acquired 46,900 shares of company stock valued at $1,368,396 over the last 90 days. 4.70% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC lifted its position in shares of Xencor by 0.7% during the fourth quarter. FMR LLC now owns 8,435,149 shares of the biopharmaceutical company’s stock worth $305,015,000 after purchasing an additional 61,233 shares in the last quarter. Vanguard Group Inc raised its holdings in Xencor by 33.0% in the third quarter. Vanguard Group Inc now owns 4,195,674 shares of the biopharmaceutical company’s stock valued at $163,506,000 after acquiring an additional 1,040,578 shares in the last quarter. Vanguard Group Inc. raised its holdings in Xencor by 33.0% in the third quarter. Vanguard Group Inc. now owns 4,195,674 shares of the biopharmaceutical company’s stock valued at $163,506,000 after acquiring an additional 1,040,578 shares in the last quarter. BlackRock Inc. raised its holdings in Xencor by 2.5% in the fourth quarter. BlackRock Inc. now owns 4,152,607 shares of the biopharmaceutical company’s stock valued at $150,159,000 after acquiring an additional 100,924 shares in the last quarter. Finally, Norges Bank purchased a new position in Xencor in the fourth quarter valued at approximately $28,271,000. 84.81% of the stock is owned by hedge funds and other institutional investors.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.

See Also: Growth Stocks, What They Are, What They Are Not

Get a free copy of the Zacks research report on Xencor (XNCR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.